10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.622.0609

WEE1 Antibody (C-term) Blocking Peptide

Synthetic peptide
Catalog # BP8106b

Specification

WEE1 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession P30291

WEE1 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 7465

Other Names
Wee1-like protein kinase, WEE1hu, Wee1A kinase, WEE1

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP8106b was selected from the C-term region of human WEE1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

WEE1 Antibody (C-term) Blocking Peptide - Protein Information

Name WEE1

Function

WEE1 Antibody (C-term) Blocking Peptide - Background

WEE1 is a nuclear protein, which is a tyrosine kinase belonging to the Ser/Thr family of protein kinases. This protein catalyzes the inhibitory tyrosine phosphorylation of CDC2/cyclin B kinase, and appears to coordinate the transition between DNA replication and mitosis by protecting the nucleus from cytoplasmically activated CDC2 kinase.

WEE1 Antibody (C-term) Blocking Peptide - References

Kawasaki, H., et al., Oncogene 22(44):6839-6844 (2003).Hashimoto, O., et al., Mol. Carcinog. 36(4):171-182 (2003).Yuan, H., et al., J. Virol. 77(3):2063-2070 (2003).Masaki, T., et al., Hepatology 37(3):534-543 (2003).de Noronha, C.M., et al., Science 294(5544):1105-1108 (2001).

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.622.0609

Acts as a negative regulator of entry into mitosis (G2 to M transition) by protecting the nucleus from cytoplasmically activated cyclin B1-complexed CDK1 before the onset of mitosis by mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a maximum during G2 phase and a minimum as cells enter M phase. Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15' and phosphorylation of monomeric CDK1 does not occur. Its activity increases during S and G2 phases and decreases at M phase when it is hyperphosphorylated. A correlated decrease in protein level occurs at M/G1 phase, probably due to its degradation.

Cellular Location
Nucleus.

WEE1 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides